SECTION 1: INITIAL EVALUATION & WORKUP (EVAL-1, EVAL-2)

Baseline Labs & Diagnostics

Test	Interpretation/Findings	Clinical Pearls
CBC with differentials (	WBC >ULN: Leukocytosis WBC>100 x109/L: Hyperleukocytosis Blast ≥20% (per WHO): AML diagnostic Blast 10-19% (per ICC): MDS/AML	Rapid cytoreduction with elevated blast counts is clinically dangerous (use hydroxyurea, leukapheresis, and/or a dose of cytarabine) Hyperleukocytosis: hydroxyurea, leukapheresis (selected symptomatic hyperleukocytosis) → if uncontrolled → one dose cytarabine (0.5-2g) Aim WBC <25 x109/L before starting therapy
CMP
Uric acid
LDH
Vitamin B12/folate
PT/PTT/fibrinogen	Screen for DIC	Critical in AML (APL)
BM biopsy + aspirate (IHC, flow cytometry, cytogenetics [conventional karyotype], FISH, NGS, multiplex panel)
Molecular testing (FLT3-ITD/TKD, NPM1, CEBPA (bZIP), IDH1/2, TP53, ASXL1, RUNX1, SRSF2, SF3B1, BCOR, EZH2, STAG2, U2AF1, ZRSR2, KIT, KRAS/NRAS, KMT2A rearrangements)
Echocardiogram or MUGA (history/symptoms of cardiac disease or planned cardiotoxic therapy)
QTc interval		QTc prolonging drugs (quizartinib or revumenib)
G6PD level		Rasburicase CI in G6PD deficiency Tumor Lysis Prophylaxis: Rasburicase (a recombinant urate oxidase enzyme) should be considered as an initial treatment in patients with rapidly increasing blast counts, high uric acid, or impaired renal function.
CNS evaluation	CT brain (rule out hemorrhage), MRI with/without contrast (if meningitis suspected), LP if symptomatic
FDG-PET/CT	If extramedullary disease suspected
HLA typing	HCT (early referral to transplant center)
CMV serology	HCT
Fertility preservation	In young patients
Palliative care integration

Complications of leukocytosis: organ dysfunction, TLS

• AML is usually diagnosed with ≥20% blasts in blood or marrow
• Under ICC, most defining recurrent genetic abnormalities require ≥10% blasts; WHO generally does not specify a minimum for most defining abnormalities, although important exceptions exist

Immediate Pharmacist Actions at Diagnosis:

APL EMERGENCY: If clinical or pathologic features of APL → START ATRA IMMEDIATELY upon first suspicion. Do NOT wait for cytogenetics. Early ATRA prevents fatal DIC/hemorrhage.
HYPERLEUKOCYTOSIS (WBC >100 x 10⁹/L): Start hydroxyurea immediately. Consider cytarabine 0.5–2 g as a bridge. Leukapheresis is controversial. WBC must be reduced to <25 x 10⁹/L before starting venetoclax (TLS risk).
TLS PROPHYLAXIS: Allopurinol or rasburicase + IV hydration. Check G6PD before rasburicase. Rasburicase preferred if: rapidly rising blasts, high uric acid, or renal impairment.

Rasburicase is contraindicated in G6PD deficiency (causes hemolytic anemia). Always check G6PD before administering. If urgency prevents lab check and G6PD deficiency is suspected, use allopurinol instead.
In APL: Do NOT give anthracycline alone without ATRA. Differentiation syndrome risk is managed with prophylactic prednisone (start with ATRA; switch to dexamethasone 10 mg IV Q12h if differentiation syndrome develops).

Finding	Interpretation	Clinical Significance
WBC elevated	Leukocytosis due to circulating blasts	High WBC (>100 x 10⁹/L) = hyperleukocytosis → leukostasis risk
WBC low or normal	AML can present with leukopenia	Do not miss AML because WBC is normal
Blasts on differential	% blasts in PB; ≥20% blasts = AML diagnosis (per WHO)	Identifies AML; circulating blasts confirm bone marrow involvement
Anemia (low Hgb)	Marrow failure → decreased RBC production	Transfusion trigger (Hgb ≤7–8 g/dL per NCCN AML-F)
Thrombocytopenia	Marrow failure → decreased platelet production	Bleeding risk; transfusion trigger <10,000/mcL; APL = DIC risk
Neutropenia (low ANC)	Normal neutrophils replaced by blasts	Immunosuppression → infection risk; febrile neutropenia management
Creatinine/BUN elevated	Renal impairment	Cytarabine dose adjustment at ≥2 g/m²; venetoclax (no adjustment but monitor); etoposide (dose reduce if CrCl <50 mL/min). TLS causes acute kidney injury
AST/ALT/Bilirubin (LFTs) elevated	Hepatic involvement or drug toxicity	Dose adjust: idarubicin (bili >2.5 mg/dL → avoid), etoposide (bili >3 → avoid), daunorubicin (bili >3 → 50% dose), GO (avoid in hepatic VOD). Also baseline before hepatotoxic therapy
Potassium high	TLS (cell lysis releases K⁺)	Hypokalemia from TLS-driven treatment (alkalinization). QTc risk with hypokalemia + FLT3 inhibitors/ATO. Hyperkalemia → cardiac arrhythmia
Phosphorus high	TLS (cells release phosphate)	Hyperphosphatemia causes hypocalcemia → tetany, seizure
Calcium low	Hypocalcemia secondary to hyperphosphatemia	Cardiac arrhythmias, neuromuscular excitability
Sodium low	SIADH (rare)	Electrolyte baseline
Glucose low	Stress hyperglycemia; steroid-related Sepsis	Affects steroid antiemetic decision
Albumin high	Malnutrition, cancer wasting	Affects drug protein binding (relevant for phenytoin, etc.)
Alk Phos low	Liver/bone involvement, VOD	GO monitoring
Uric acid Elevated at diagnosis	High tumor burden, spontaneous cell turnover	Start allopurinol or rasburicase IMMEDIATELY. Elevated baseline uric acid = TLS risk classification as high
Uric acid Rapidly rising	Leukemic cells dying → TLS imminent	Rasburicase preferred (faster-acting, directly degrades uric acid to soluble allantoin)
Uric acid Normal	Baseline; does not rule out TLS after chemotherapy	Still start prophylaxis before treatment
LDH Very high (>2x ULN)	High leukemic burden; rapid cell turnover → HIGH TLS risk. Also associated with worse prognosis per NCCN Discussion (prognostic relevance)
PT prolonged	Clotting factor depletionDIC consuming factors II, V, VII, X

In APL specifically, thrombocytopenia + coagulopathy = potentially fatal DIC. The CBC directs the URGENCY of treatment (especially platelet transfusion trigger).
Uric Acid Role: Uric acid is the end product of purine metabolism. When leukemic blasts die rapidly (spontaneously or from chemotherapy), nucleic acids are released → broken down to hypoxanthine/xanthine → uric acid. Uric acid elevation crystallizes in renal tubules → obstructive nephropathy → acute kidney injury. This is a PREVENTABLE cause of renal failure.
LDH (Lactate Dehydrogenase) Role: LDH is an intracellular enzyme released when cells lyse. It is a direct marker of tumor burden and cellular turnover.
LDH + uric acid together define the spontaneous TLS risk BEFORE chemotherapy starts. Together with WBC and blast count, they guide whether you use allopurinol vs. rasburicase.
PT/PTT/Fibrinogen Role: Coagulation screen to detect DIC — which is LIFE-THREATENING in AML, and near-universal in APL.

ELN 2022 RISK STRATIFICATION (AML-A)

Source: NCCN AML v3.2026 AML-A | ELN 2022 (Döhner H, et al. Blood 2022)

⚡ KEY CONCEPT: ELN 2022 risk stratification drives BOTH induction regimen selection AND post-remission strategy (alloHCT vs consolidation chemo). Every AML patient requires cytogenetics + NGS at diagnosis.

Risk Category	Cytogenetic/Molecular Features	Post-Remission Implication
FAVORABLE	t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 inv(16)(p13.1q22) or t(16;16)/CBFB::MYH11 Mutated NPM1 (without FLT3-ITD) bZIP in-frame mutated CEBPA	HiDAC consolidation preferred over alloHCT in CR1 (unless MRD+). Add GO(CD33+) to induction (category 1 preferred).
INTERMEDIATE	Mutated NPM1 with FLT3-ITD Wild-type NPM1 with FLT3-ITD (no adverse lesions) t(9;11)(p21.3;q23.3)/MLLT3::KMT2A Cytogenetic/molecular NOS (not favorable or adverse)	AlloHCT in CR1 generally recommended. FLT3 inhibitor (midostaurin or quizartinib) added to induction and maintenance.
POOR/ ADVERSE	t(6;9)(p23.3;q34.1)/DEK::NUP214 t(v;11q23.3)/KMT2A-rearranged (non-MLLT3) t(9;22)/BCR::ABL1 t(8;16)(p11.2;p13.3)/KAT6A::CREBBP inv(3)/t(3;3)/GATA2, MECOM(EVI1) -5 or del(5q); -7; -17/abn(17p) Complex karyotype (≥3 abnormalities); monosomal karyotype Mutated: ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2 Mutated TP53 → strongly consider clinical trial	AlloHCT in CR1 (if achieved). CPX-351 preferred for secondary/therapy-related AML in age ≥60 y (category 1). TP53-mutant: no preferred regimen; clinical trial strongly recommended.

CEBPA: Only bZIP in-frame mutations confer favorable risk per ELN 2022. ingle vs biallelic mutation distinction was removed. Verify the mutation type on the molecular report.
FLT3-ITD: Intermediate risk regardless of allelic ratio per ELN 2022. However, high allelic ratio (>0.5) historically associated with worse outcomes – some centers treat more aggressively.
TP53 mutation: Lowest benefit category for venetoclax-based regimens per AML-J. Clinical trial is the preferred recommendation. No standard regimen has demonstrated clear superiority.
KIT mutation: In CBF-AML (t(8;21) or inv(16)), KIT mutation is associated with worse prognosis but does NOT change risk category per ELN 2022 – monitor for emerging data.
Venetoclax Benefit by Mutation (AML-J): Higher benefit = TP53-wild, KRAS-wild, NRAS-wild, FLT3-ITD-negative. Intermediate = KRAS/NRAS mutated or FLT3-ITD+, TP53-wild. Lower benefit = TP53-mutant.

TREATMENT DECISION ALGORITHM (AML1 → AML9)

Source: NCCN AML v3.2026 AML-1 through AML-9

3.1 Intensive Induction Eligible (Fit Patients)

Key eligibility criteria: ECOG PS 0–2, adequate organ function, no major contraindications to intensive chemotherapy. Age alone does not preclude intensive therapy.

Favorable/Intermediate Risk (AML-1):

• Preferred: 7+3 (daunorubicin or idarubicin) + gemtuzumab ozogamicin (CD33+)
• Other Recommended: 7+3 alone | FLAG-IDA ± gemtuzumab ozogamicin | CLAG-M
• FLT3 mutation: 7+3 + midostaurin (ITD or TKD) OR 7+3 + quizartinib (ITD only)

Poor/Adverse Risk – Without TP53 (AML-2):

• Age ≥60 y: CPX-351 preferred (category 1) | Age <60 y: 7+3 preferred
• Also recommended: Aza+Ven | Dec+Ven | CLIA+Ven | FLAG-IDA+Ven (use with caution >60 y)

Poor/Adverse Risk – TP53 Mutated (AML-2):

• CLINICAL TRIAL is the preferred recommendation
• Other recommended: 7+3 | CPX-351 (2B) | Flag-IDA (2B) | Aza+Ven | Dec+Ven | CLAG-M | CLIA+Ven

3.2 Intensive Induction Ineligible or Patient Declines (AML-4)

Lower-intensity therapy options – organized by FDA approval status and evidence level:

Regimen	Dosing (NCCN AML-E)	Indication/Notes
Aza + Venetoclax	Aza 75 mg/m² SC/IV D1–7 of 28-day cycle; Ven PO 100→200→400 mg ramp-up D1-3	Preferred. FDA approved. VIALE-A trial (OS benefit). Inpatient cycle 1 strongly recommended.
Dec + Venetoclax	Dec 20 mg/m² IV D1–5 (or D1–10); Ven PO 100→200→400 mg ramp-up D1–3	Preferred. FDA approved (D1–5). VIALE-A/phase 1b data.
Aza + Ivosidenib (IDH1+)	Aza 75 mg/m² D1–7 or D1–5,8,9; Ivo 500 mg PO QD D1–28	Category 1 preferred. FDA approved. AgIQ trial. Criteria: age >75, ECOG 2, severe cardiac/pulmonary, bilirubin >1.5 ULN, CrCl <45, or comorbidity.
Aza monotherapy	75 mg/m² SC/IV D1–7 of 28-day cycle	Alternative if venetoclax contraindicated.
Dec monotherapy	20 mg/m² IV D1–5 of 28-day cycle	Alternative if venetoclax contraindicated.
Ivosidenib (IDH1+)	500 mg PO QD D1–28	Monotherapy for IDH1-mutant AML.
Olutasidenib (IDH1+)	150 mg PO BID D1–28	IDH1-mutant AML. Monitor QTc.
Enasidenib (IDH2+)	100 mg PO QD D1–28	IDH2-mutant AML. Risk of differentiation syndrome.
Aza + Enasidenib (IDH2+)	Aza 75 mg/m² D1–7 + Enasidenib 100 mg PO QD D1–28	IDH2-mutant AML.
Gilteritinib (FLT3+)	120 mg PO QD D1–28	FLT3-ITD or TKD mutation.
Gilteritinib + Aza (FLT3+)	120 mg PO QD D1–28 + Aza 75 mg/m² D1–7	FLT3-ITD or TKD mutation.
LDAC + Venetoclax	LDAC 20 mg/m²/day SC D1–10; Ven ramp-up 100→200→400→600 mg D1–4	Preferred if HMA not feasible.
LDAC + Glasdegib	LDAC 20 mg SC Q12h D1–10 + Glasdegib 100 mg PO QD D1–28	CLARITY trial. Alternative option.
Gemtuzumab Ozogamicin (CD33+)	6 mg/m² D1 + 3 mg/m² D8	Single-agent option in lower intensity setting.
Cladribine + LDAC + Ven	Clad 5 mg/m² D1–5 + LDAC 20 mg SC BID D1–10 + Ven D1–21 (induction); complex alternating consolidation schedule	Induction + multiple alternating consolidation courses.

DETAILED DOSING OF KEY REGIMENS (AML-E)

Source: NCCN AML-E 1–10 of 14 | v3.2026

4.1 Standard 7+3 Induction

Drug	Dose	Route	Schedule	Key Notes
Cytarabine	100 or 200 mg/m²/day	IV continuous infusion	Days 1–7	200 mg/m² preferred by many centers; both doses are guideline options.
Daunorubicin	60 mg/m²/day* or 90 mg/m² (<60 y)	IV	Days 1–3	*ECOG: 90 mg/m² superior in <60 y (OS benefit). For >65y: 60 mg/m² preferred (no benefit from 90 mg/m²). 60 mg/m² now preferred by some over 90 mg/m².
OR Idarubicin	12 mg/m²/day	IV	Days 1–3	Equivalent to daunorubicin 90 mg/m² for ages 60–65. Preferred at many centers.

Reinduction (residual disease on D14 BM biopsy): Cytarabine CI x additional days + daunorubicin 45 mg/m² x 2 (if 90 mg/m² used in induction) or idarubicin 10 mg/m² x 1–2 doses.

4.2 7+3 + Gemtuzumab Ozogamicin (GO)

• GO 3 mg/m² (max one 4.5-mg vial) IV on Day 1, 2, 3, OR 4; OR Days 1, 4, and 7 (3 doses total)
• GCD33-positive tumors only – verify CD33 expression by flow cytometry or IHC

⚠️ PHARMACIST WATCHOUT: GO is a vesicant-like agent with risk of hepatic sinusoidal obstruction syndrome (SOS/VOD). Monitor LFTs closely. Premedicate per institutional protocol (acetaminophen + diphenhydramine). Infuse over 2 hours. If VOD develops → defibrotide.

💎 CLINICAL PEARL: GO single dose 3 mg/m² on ONE day vs. 3-dose schedule: NCCN allows both. Meta-analysis (Hills et al., Lancet Oncol 2014) showed OS benefit with GO in favorable/intermediate risk. Maximum benefit in favorable risk (CBF-AML).

4.3 7+3 + FLT3 Inhibitors

A. Midostaurin (FLT3-ITD or TKD) – RATIFY Trial

Drug	Dose	Route	Schedule
Midostaurin	50 mg PO Q12h	PO with food	Days 8–21 (during induction and consolidation cycles)
Continue as maintenance	50 mg PO Q12h	PO	Days 1–28 x 12 cycles post-alloHCT/consolidation

Midostaurin is a CYP3A4 substrate. Significant DDI with azole antifungals (posaconazole, voriconazole, fluconazole – CYP3A4 inhibitors) → increases midostaurin exposure. Balance infection risk vs. DDI; institutional protocols vary (often switch to micafungin).

RATIFY Trial (Stone et al., NEJM 2017): Midostaurin + 7+3 improved OS (HR 0.78) and EFS vs. placebo in FLT3+ newly diagnosed AML. Benefit seen regardless of FLT3-ITD allelic ratio or FLT3-TKD.

B. Quizartinib (FLT3-ITD ONLY) – QuANTUM-First Trial

Drug	Dose	Route	Schedule	Key Notes
Quizartinib (induction)	35.4 mg PO QD	PO	Days 8–21	QTcF must be ≤450 ms before starting
Quizartinib (maintenance)	26.5 mg → 53 mg PO QD	PO	D1–28 per cycle (up to 36 cycles)	Cycle 1 D1–14: 26.5 mg if QTcF ≤450. If QTcF ≤450 on D15 → escalate to 53 mg. Maintain 26.5 mg if QTcF ever >500 ms.

QUIZARTINIB: QTc PROLONGATION IS A MAJOR CONCERN. QTcF >500 ms → hold/dose-reduce. Avoid concomitant QT-prolonging agents. Strong CYP3A4 inhibitors increase quizartinib levels. Electrolyte repletion (K+, Mg²+) is mandatory.

QuANTUM-First Trial (Erba et al., Lancet 2023): Quizartinib + 7+3 improved OS in newly diagnosed FLT3-ITD AML (HR 0.78). FLT3-ITD SPECIFIC – do NOT use for FLT3-TKD. Note: quizartinib is ITD-selective; midostaurin covers both ITD and TKD.

4.4 CPX-351 (Dual-Drug Liposomal Cytarabine + Daunorubicin)

Drug	Dose	Route	Schedule	Notes
CPX-351	Cytarabine 100 mg/m² + Daunorubicin 44 mg/m²	IV over 90 minutes	Days 1, 3, 5 (x 1 cycle induction)	Fixed 5:1 molar ratio (cytarabine:daunorubicin). Do NOT substitute with separate agents.

• Preferred for: Age ≥60 y with therapy-related AML, AML with myelodysplasia-related changes (AML-MRC), antecedent MDS/CMML (category 1)
• Also appropriate for age <60 y with poor-risk features

CPX-351 is NOT the same as conventional 7+3. The liposomal formulation has different PK, longer half-life, and different toxicity profile. Do NOT dose-modify or substitute components. Monitor for extended myelosuppression (longer time to count recovery expected).
ANTHRACYCLINE CUMULATIVE DOSE: Convert CPX-351 daunorubicin dose to conventional units when calculating lifetime anthracycline exposure for cardiac risk assessment. Assess LVEF before treatment.

ADMIRAL Trial (Lancet 2020): CPX-351 vs. 7+3 in secondary AML (therapy-related or MDS/CMML-related). Improved median OS (9.56 vs. 5.95 months) and higher rate of alloHCT. Category 1 for age ≥60 y.

4.5 FLAG-IDA & FLAG-IDA + Venetoclax

Drug	Dose	Route	Days	Notes
Fludarabine	30 mg/m²	IV	Days 2–6	In fludarabine shortage: substitute cladribine (CLAG-M).
Cytarabine (HiDAC)	2 g/m²	IV over 4 hours	Days 2–6 (start 4h after fludarabine)	Use with CAUTION in ≥60 y or renal failure → cerebellar neurotoxicity risk. Steroid eye drops.
Idarubicin	8 mg/m²	IV	Days 4–6	Anthracycline component.
G-CSF (filgrastim)[ZA20]	SC	SC	Days 1–7	G-CSF acts as a sensitizer, recruits leukemic cells into cycle (GCSF-priming strategy).
Venetoclax (if added)	100 mg D1 → 200 mg D2 → 400 mg D3–7	PO	Days 1–7	Ramp-up required. Use with caution in >60 y. Venetoclax + FLAG-IDA: intensive regimen, significant cytopenias expected.

HiDAC CYTARABINE NEUROTOXICITY: Cerebellar toxicity (nystagmus, ataxia, dysarthria, dysmetria) more common in age ≥60 y or renal impairment. MANDATORY neuro exam before EACH dose. If ANY cerebellar signs → STOP cytarabine immediately. Do NOT rechallenge.
STEROID EYE DROPS: All patients receiving cytarabine ≥2 g/m² MUST receive prophylactic steroid eye drops (e.g., prednisolone 1% 2 drops to each eye QID) starting Day 1 until 24–72 hours post-completion. Failure to prescribe → chemical conjunctivitis.

4.6 MEC Regimen – NCCN Template AML34 (Relapsed/Refractory)

NCCN Chemotherapy Order Template AML34 | NCCN AML v1.2026

Drug	Dose	Route	Schedule (Option A, Days 1–5)	Schedule (Option B, Days 1–6)
MitoXANTRONE	8 mg/m²/day (A) OR 6 mg/m²/day (B)	IV over 30 min	Days 1–5	Days 1–6
Etoposide	100 mg/m²/day (A) OR 80 mg/m²/day (B)	IV over 60 min	Days 1–5	Days 1–6
Cytarabine (HiDAC)	1,000 mg/m²/day	IV over 3 hours	Days 1–5 (given AFTER etoposide)	Days 1–6 (given AFTER etoposide)

MEC Supportive Care (per NCCN AML34):

• Steroid eye drops: Prednisolone 1% 2 drops to EACH eye QID D1 of cytarabine, until 24–72 hours post-completion
• Moderate emetic risk:Antiemetics: Days 1–5 (Option A) or Days 1–6 (Option B): Dexamethasone dose may be modified or omitted (controversial in AML due to immunosuppression)
• TLS prophylaxis: Hydration + allopurinol (or rasburicase if high risk). Monitor electrolytes daily until TLS risk passes
• Mucositis monitoring: MEC-associated mucositis risk. Oral care protocols, topical mouthwashes, opioids, IV hydration as needed
• Central venous access device (CVAD) recommended for this regimen

MEC Monitoring (per NCCN AML34):

• CBC with differential: as clinically indicated
• Electrolytes, uric acid, renal function: at least DAILY (until TLS risk resolved)
• LFTs: prior to each cycle and as clinically indicated (for MitoXANTRONE and etoposide dose adjustments)
• Neurological exam: before each cytarabine dose (cerebellar toxicity monitoring)
• Renal function: prior to each cycle (etoposide and cytarabine dose modification)
• LVEF: prior to initiation (mitoXANTRONE is anthracycline-like – monitor cumulative anthracycline dose)

MEC Pharmacist Safety Watchouts (NCCN AML34):

MitoXANTRONE is a VESICANT – verify CVAD placement and patency before administration. Extravasation can cause severe tissue damage.
MitoXANTRONE cumulative cardiotoxicity: monitor total lifetime anthracycline equivalents. LVEF assessment required before initiation. Secondary malignancies associated with mitoXANTRONE (package insert review required).
Etoposide is an IRRITANT. Must be administered through NON-PVC tubing (plasticizer leaching). Monitor for hypersensitivity/infusion reactions: anaphylaxis, hives, throat tightness, hypotension. Secondary malignancies (therapy-related AML/MDS) associated with etoposide.
Etoposide hypersensitivity: reduce infusion rate (over 60 min minimum), have epinephrine/diphenhydramine/steroids available. If reaction occurs → slow/stop infusion, premedicate, consider rechallenge per institutional protocol.
LFT monitoring for etoposide: hepatic impairment → dose reduction required. Check total bilirubin, AST/ALT before each cycle.

MEC emetic risk is MODERATE (5- or 6-day regimen). Dexamethasone as antiemetic is controversial in AML due to immunosuppression. Consult NCCN Antiemesis guidelines. Consider 5-HT3 antagonists (ondansetron, granusetron) ± NK1 antagonist without steroids.

CONSOLIDATION & MAINTENANCE THERAPY

Source: NCCN AML v3.2026 AML-6, AML-7, AML-E 6–7 of 14

5.1 Consolidation – Intensive Induction Eligible (AML-6)

Risk Category	Preferred Consolidation	Notes
Favorable (CBF-AML, NPM1+, CEBPA bZIP)	HiDAC 3 g/m² IV over 3h Q12h Days 1,3,5 x 3–4 cycles	AlloHCT not required in CR1 for MRD-negative favorable risk. 3 g/m² ≥60 y: use 1–1.5 g/m² to reduce neurotoxicity.
Intermediate Risk (FLT3-ITD, others)	AlloHCT in CR1 preferred. Pre-HCT: HiDAC 1–3 g/m²	FLT3 inhibitor maintenance post-HCT (gilteritinib preferred if FLT3-MRD+).
Poor/Adverse Risk	AlloHCT in CR1 strongly preferred	CPX-351: If consolidation chemo needed, 1 cycle CPX-351 can be used (65 mg/m² day 1, 3). FLAG-IDA data also available.
Secondary/Therapy-related AML	AlloHCT preferred | or CPX-351 consolidation	CPX-351 consolidation: 65 mg/m² (cytarabine equivalent) Days 1, 3 IV over 90 min.

HiDAC 3 g/m² Q12h in patients ≥60 years or CrCl <60 mL/min → HIGH neurotoxicity risk (cerebellar ataxia, confusion). Reduce to 1–1.5 g/m² per NCCN guideline footnote. Mandatory neuro exam prior each dose.

There is no evidence that cytarabine doses ≥2 g/m² are superior to 1–2 g/m² in intermediate-risk AML per NCCN footnote (AML-E 6A). For adverse risk, HiDAC is bridge to alloHCT, not definitive therapy.

5.2 Maintenance Therapy (AML-7)

Drug	Dose/Schedule	Indication	Duration	Key Notes
Oral Azacitidine (CC-486)	300 mg PO QD Days 1–14 of 28-day cycle	CR/CRi post-chemotherapy (no alloHCT)	Continue until relapse/toxicity	QUAZAR AML-001 trial (Wei et al., NEJM 2020): OS benefit (24.7 vs. 14.8 months). Approved for AML in CR/CRi post-intensive therapy, age ≥55 y, not eligible for HCT.
Gilteritinib (FLT3-ITD/TKD)	120 mg PO QD Days 1–28	Post-alloHCT or post-consolidation, FLT3+ AML	Up to 26 cycles	ADMIRAL trial maintenance data + FLT3-MRD-guided use. New NCCN: recommended post-HCT if FLT3-ITD MRD ≥10⁻⁶ by NGS (sensitivity ≤10⁻⁵).
Quizartinib (FLT3-ITD only)	26.5 mg → 53 mg PO QD D1–28	Post-consolidation, FLT3-ITD only	Up to 36 cycles	QTcF monitoring mandatory. Cycle 1 D1–14: 26.5 mg; escalate to 53 mg if QTcF ≤450 ms on D15.
Midostaurin (FLT3-ITD/TKD)	50 mg PO BID D1–28	Post-consolidation, FLT3+ AML	12 cycles	RATIFY protocol. DDI with azoles (see above).
Sorafenib (FLT3-ITD only)	200 mg BID x3 cycles → 400 mg BID	Post-alloHCT, FLT3-ITD	Up to 24 months	Off-label; limited by toxicity (hypertension, hand-foot syndrome, diarrhea).
Azacitidine SC	50 mg/m² SC D1–5 of 28-day cycle	Post-remission (non-HCT eligible)	Max 12 cycles	Alternative to oral azacitidine.
Decitabine	20 mg/m² IV D1–5 of 28–56-day cycle; or D1–3 of 28-day cycle	Post-remission maintenance	Max 12 cycles	Alternative option; less evidence than oral aza.
Low-dose decitabine	5 mg/m² IV D2–6 + G-CSF SC D1–6	Maintenance option	Variable	NCCN listed; institutional use.

QUAZAR AML-001: Oral azacitidine 300 mg (NOT same as injectable 75 mg/m²). Oral formulation has different bioavailability. Do NOT substitute injectable formulation for oral. Brand name: Onureg.
Remission status: G-CSF must be stopped ≥7 days before BM biopsy to assess remission status (to avoid confounding neutrophil recovery with persistent disease).

SECTION 6: VENETOCLAX PRINCIPLES (AML-J)

Source: NCCN AML v3.2026 AML-J 1–4 of 4 | VIALE-A Trial (DiNardo et al., NEJM 2020)

6.1 Venetoclax Ramp-Up Dosing

Day	Ven + HMA (Aza or Dec)	Ven + LDAC	Purpose
Day 1	100 mg PO once daily	100 mg PO once daily	Ramp-up to minimize TLS risk
Day 2	200 mg PO once daily	200 mg PO once daily
Day 3	400 mg PO once daily	400 mg PO once daily
Day 4+	400 mg PO once daily	600 mg PO once daily	LDAC uses higher target dose (600 mg)

6.2 TLS Risk & Monitoring (Cycle 1)

• Reduce WBC to <25 x 10⁹/L with hydroxyurea/leukapheresis BEFORE starting venetoclax
• INPATIENT treatment strongly recommended for Cycle 1 (especially through ramp-up)
• Allopurinol or other uric acid–lowering agent until no further TLS risk
• Monitor blood chemistries (electrolytes, uric acid, creatinine, phosphorus, LDH) every 6–8 hours x 24 hours after maximum dose escalation; then daily until TLS risk resolved
• Aggressively manage electrolyte imbalances (K+, phosphorus, Ca²+, uric acid)

6.3 Cycle Management & Dose Modifications (AML-J 3 of 4)

Situation	Action
BM day 21–28 shows CR	Delay cycle 2 up to 14 days for ANC >0.5 x 10⁹/L and platelets >50 x 10⁹/L. G-CSF encouraged. Consider reducing venetoclax duration to 21 days.
BM day 21–28 shows MLFS or CRi	Start cycle 2 without delay. Continue monitoring.
Cycle 3+: cytopenias recur	Delay next cycle up to 14 days for ANC/plt recovery. G-CSF encouraged. Reduce venetoclax duration: 14 days → 7 days → 5 days as needed.
Substantial comorbidities (new)	Consider initiating venetoclax at reduced duration (e.g., 7 days) per AML-J 2 of 4.
Lack of response after ≤4 cycles	Consider switch to R/R therapy (AML-9). Response most commonly seen after 2 cycles; reasonable to stop after 2 cycles if no response.
Concurrent strong CYP3A4 inhibitor (e.g., posaconazole, voriconazole, ketoconazole)	Reduce venetoclax to 70 mg (if on 400 mg) or reduce accordingly per package insert. Consult pharmacist.
Concurrent moderate CYP3A4 inhibitor (e.g., fluconazole, diltiazem, erythromycin)	Reduce venetoclax by ~50%. Consult package insert and pharmacist.
Strong CYP3A4 inducers (carbamazepine, phenytoin, rifampin)	AVOID – significantly reduces venetoclax efficacy.
P-gp inhibitors (e.g., amiodarone, clarithromycin)	Use with caution; may increase venetoclax levels.

VENETOCLAX DDI – HIGH PRIORITY: Azole antifungals (posaconazole = strong CYP3A4 inhibitor; fluconazole = moderate) INCREASE venetoclax levels significantly. DOSE ADJUSTMENT IS MANDATORY. Document dose reduction in the chart. Failure to adjust → severe myelosuppression and potentially fatal TLS.
TUMOR LYSIS SYNDROME (TLS): Venetoclax-based regimens in AML carry HIGH TLS risk in cycle 1. This is different from venetoclax in CLL (which uses a 5-week ramp-up as outpatient). In AML, inpatient monitoring during ramp-up is strongly recommended per NCCN.

VIALE-A Trial (DiNardo et al., NEJM 2020): Aza + Venetoclax improved OS (14.7 vs. 9.6 months) and CR rate (36.7% vs. 17.9%) vs. azacitidine alone in treatment-naive, intensive therapy-ineligible AML. Subgroup analysis: highest benefit in NPM1-mutant, IDH1/2-mutant AML. Lowest benefit in TP53-mutant AML.
PROGNOSTIC STRATIFICATION for HMA+Ven benefit (AML-J 1 of 4 – NEW in v3.2026): Higher benefit = negative for TP53, KRAS, NRAS, FLT3-ITD. Intermediate = KRAS/NRAS or FLT3-ITD+, TP53-wild. Lower benefit = TP53-mutant. This guides counseling and alternative considerations.

SECTION 7: RELAPSED / REFRACTORY AML (AML-8, AML-9)

Source: NCCN AML v3.2026 AML-9, AML-E 8–10 of 14

7.1 Targeted Therapies in R/R AML

Drug	Target	Dose	Key Pharmacist Note
Gilteritinib (Xospata)	FLT3-ITD or TKD	120 mg PO QD D1–28 (28-day cycle)	ADMIRAL trial: improved OS vs. salvage chemo in R/R FLT3+ AML. QTc monitoring. CYP3A4 substrate. Risk of differentiation syndrome (similar to IDH inhibitors). Avoid strong CYP3A4 inducers.
Quizartinib (Vanflyta)	FLT3-ITD only	26.5→53 mg PO QD (QTcF-guided)	QTc prolongation: dose at 26.5 mg D1–14; escalate to 53 mg if QTcF ≤450 ms D15. Maintain 26.5 mg if QTcF ever >500 ms. Strong DDI with CYP3A4 inhibitors.
Enasidenib (Idhifa)	IDH2 mutation	100 mg PO QD D1–28	IDH-INHIBITOR DIFFERENTIATION SYNDROME RISK (fever, SOB, pulmonary infiltrates, lymphadenopathy, edema). Treat with dexa 10 mg IV Q12h. Do NOT stop enasidenib unless severe. Leukocytosis may occur.
Ivosidenib (Tibsovo)	IDH1 mutation	500 mg PO QD D1–28	Same differentiation syndrome risk as enasidenib. Also QTc prolongation risk. Strong CYP3A4 inhibitors increase levels. Food reduces absorption – take on empty stomach or consistent with meals.
Olutasidenib (Rezlidhia)	IDH1 mutation	150 mg PO BID D1–28	IDH1-specific. QTc monitoring required. Take with or without food. Approval based on AUGMENT-101 trial.
Revumenib (Revuforj)	KMT2A rearrangement or NPM1 mutation	160 mg PO BID (with strong CYP3A4 inh) OR 270 mg PO BID (without strong CYP3A4 inhibitor)	DOSE IS DIFFERENT based on co-administration of strong CYP3A4 inhibitor! Weight-based dosing for <40 kg patients. Differentiation syndrome risk. QTc prolongation. FDA approved 2023 for R/R AML.
Ziftomenib (Zilbrysq) new	NPM1 mutation	600 mg PO QD D1–28	NPM1-mutant AML (R/R). FDA approved 2025. Differentiation syndrome risk. New drug – monitor for updates on DDI profile.
Gemtuzumab Ozogamicin (GO – Mylotarg)	CD33-positive	3 mg/m² (≤4.5 mg vial) D1, 4, 7 (R/R setting)	VOD/SOS risk – monitor LFTs, weight gain, RUQ pain. CD33 must be verified. Infuse over 2 hours. Premedicate.
Azacitidine or Dec + Sorafenib (FLT3-ITD)	FLT3-ITD (off-label combination)	Aza 75 mg/m² D1–7 or Dec 20 mg/m² D1–10 + Sorafenib 400 mg PO BID	NCCN listed. Sorafenib toxicities: hypertension, hand-foot syndrome, diarrhea, hepatotoxicity. QTc monitoring. CYP3A4 substrate/inhibitor.

7.2 Intensive Salvage Regimens in R/R AML (AML-E 9 of 14)

Regimen	Dosing	Key Notes
MEC (NCCN AML34)	MitoXANTRONE 8 mg/m² (or 6 mg/m²) + Etoposide 100 mg/m² (or 80 mg/m²) + Cytarabine 1,000 mg/m² D1–5 (or D1–6)	Moderate emetic risk. CVAD required.
CLAG ± Mitoxantrone/ Idarubicin	Cladribine 5 mg/m² D2–6 + Cytarabine 2 g/m² D2–6 (2h after cladribine) + G-CSF D1–6 ± Mitoxantrone 10 mg/m² or Idarubicin 8 mg/m² D2–4	Use with caution ≥60 y. Cytarabine ≥2 g/m² neurotoxicity risk.
FLAG ± Idarubicin	Fludarabine 30 mg/m² D2–6 + Cytarabine 2 g/m² D2–6 (4h after fludarabine) + G-CSF D1–5 ± Idarubicin 10 mg/m² D1–3	Cladribine substitutable for fludarabine.
HiDAC ± Daunorubicin or Idarubicin	Cytarabine 2–3 g/m² Q12h D1–6 ± Daunorubicin 50 mg/m² or Idarubicin 12 mg/m² x3 days	HiDAC. Strict neuro monitoring. Steroid eye drops mandatory.
HiDAC ± Mitoxantrone	Cytarabine 1.5–3 g/m² Q12h D1–6 ± Mitoxantrone 10 mg/m² D7–9

REVUMENIB: Dose depends on whether the patient is receiving a strong CYP3A4 inhibitor (azole antifungals). If on posaconazole/voriconazole → 160 mg BID. If NOT → 270 mg BID. This is a critical counseling point. Differentiation syndrome risk is significant.
DIFFERENTIATION SYNDROME with IDH inhibitors (ivosidenib, enasidenib, olutasidenib) and FLT3 inhibitors (gilteritinib): Can mimic sepsis. Features: fever, pulmonary infiltrates, hypoxia, weight gain, edema, pleuritis. Treatment: dexamethasone 10 mg IV Q12h until resolution. Do NOT stop the inhibitor unless grade 3–4 despite steroids.
QTc MONITORING CHECKLIST for R/R AML: Quizartinib → mandatory QTcF. Ivosidenib → QTc prolongation. Olutasidenib → QTc monitoring. Sorafenib → QTc. Revumenib → QTc. Obtain baseline ECG and replete K+/Mg²+ before any of these agents.

SECTION 8: ACUTE PROMYELOCYTIC LEUKEMIA (APL)

Source: NCCN AML v3.2026 APL-1 through APL-6 | APL-A, APL-B. More details here

8.1 Risk Stratification & Treatment Selection

Risk	Definition	Induction Regimen
Low Risk	WBC ≤10 x 10⁹/L, No cardiac issues	ATRA + Arsenic Trioxide (ATO) – Category 1 (Preferred) OR ATRA + Idarubicin (if ATO unavailable/contraindicated)
High Risk	WBC >10 x 10⁹/L	ATRA + Idarubicin + ATO or cytarabine (per protocol) (See APL-3 for full protocol details)
Cardiac Issues (Low EF or QTcF prolongation)	Any WBC + cardiac issues	Alternative induction: see APL-4 (modified regimen)

8.2 APL Induction – Low Risk (ATRA + ATO, Category 1)

Drug	Dose	Schedule	Phase
ATRA (tretinoin)	45 mg/m²/day PO divided BID	Until clinical remission (typically ~28 days)	Induction + Consolidation
Arsenic Trioxide (ATO)	0.15 mg/kg IV QD	Days 1–28 (induction); intermittent schedule (consolidation)	Induction + Consolidation
Idarubicin (if ATO unavailable)	12 mg/m²/day	Days 2, 4, 6, 8 (every other day)	Alternative induction
Gemtuzumab Ozogamicin	Per APL-2 protocol	Alternative if arsenic contraindicated	Useful in certain circumstances

Key APL Management Points:

• Start ATRA at FIRST SUSPICION – do not wait for confirmatory cytogenetics/FISH/PCR
• Begin steroid prophylaxis (prednisone) at ATRA initiation – differentiation syndrome prevention
• BM assessment Day 28–35 to document <5% blasts and no abnormal promyelocytes before consolidation
• Presence of molecular markers (PML::RARA) post-induction does NOT have prognostic implications (unlike AML)
• FLT3 inhibitors are NOT recommended for FLT3-positive APL (per NCCN footnote)
• For high cumulative anthracycline doses: reassess cardiac function before each anthracycline/mitoxantrone-containing course

APL DIFFERENTIATION SYNDROME: Occurs with ATRA and/or ATO. Features: fever ≥38°C, dyspnea, weight gain ≥5 kg, pulmonary infiltrates, pleural/pericardial effusion, hypotension. Treat with dexamethasone 10 mg IV Q12h at FIRST SIGN. Generally do NOT discontinue ATRA/ATO for mild-moderate syndrome.
ATO (Arsenic Trioxide) QTc PROLONGATION: Obtain baseline ECG. QTcF >500 ms → HOLD ATO and correct electrolytes. Monitor K+, Mg²+, Ca²+ daily during ATO treatment. Avoid concomitant QT-prolonging drugs.
APL COAGULOPATHY: APL is associated with FATAL HEMORRHAGE secondary to DIC + hyperfibrinolysis. Monitor PT/PTT/fibrinogen/D-dimer DAILY. Platelet target >50,000/mcL. Fibrinogen target >150 mg/dL. Cryoprecipitate and FFP as needed.

Lo-Coco et al. (NEJM 2013) and Platzbecker et al. (JCO 2017): ATRA+ATO is non-inferior to ATRA+chemotherapy in low-risk APL with BETTER tolerability and OS. Chemotherapy-free approach for low-risk APL is now the global standard.

SECTION 9: SUPPORTIVE CARE (AML-F)

Source: NCCN AML v3.2026 AML-F, AML-G

Supportive Care Element	NCCN Recommendation	Pharmacist Watchout
Transfusion – RBC	Threshold: Hgb ≤7–8 g/dL (or per symptoms)	Use leukocyte-depleted products. CMV-seronegative products for HCT candidates. Irradiated for potential HCT or alloimmunized.
Transfusion – Platelets	Threshold: Plt <10,000/mcL OR any bleeding signs	Alloimmunized patients: HLA-matched or cross-match-compatible products.
TLS Prophylaxis	Hydration + Allopurinol (or rasburicase for high-risk)	G6PD check before rasburicase. Rasburicase CI: G6PD deficiency, pregnancy. Rasburicase contraindicated with allopurinol (use one or the other).
Central Venous Access (CVAD)	Recommended (multi-lumen) for all intensive therapy	Assess for line infection. Thrombosis monitoring. Remove/replace per clinical circumstances.
HiDAC Eye Prophylaxis	Prednisolone 1% drops BID to EACH eye starting D1 through 24–72h post-cytarabine completion	Must be ordered with EACH high-dose cytarabine course. Chemical conjunctivitis is preventable. Applies to ≥2 g/m² doses.
Cytarabine Neurotoxicity	Neuro exam (nystagmus, ataxia, dysarthria, dysmetria) before EACH HiDAC dose	STOP cytarabine permanently if cerebellar toxicity. No rechallenge with ≥2 g/m². Elevated creatinine during TLS → HOLD cytarabine ≥2 g/m² until creatinine normalizes.
Antifungal Prophylaxis	Posaconazole shown to significantly decrease fungal infections vs. fluconazole/itraconazole	Posaconazole = strong CYP3A4 inhibitor → adjust venetoclax, midostaurin, quizartinib, ivosidenib doses. Voriconazole, echinocandins, or AmBisome are alternatives.
Antibacterial Prophylaxis	Per institutional protocol and prevailing resistance patterns	Fluoroquinolone prophylaxis (levofloxacin) widely used but consider resistance. Review for DDI with QTc-prolonging agents.
Antiviral Prophylaxis	Acyclovir/valacyclovir (per institutional protocol, especially post-HCT)	Acyclovir dose adjustment in renal impairment.
PCP Prophylaxis	Consider during fludarabine-containing regimens and post-HCT	TMP-SMX preferred. If sulfa allergy: atovaquone or dapsone (check G6PD for dapsone).
G-CSF / Growth Factors	May be used in post-remission therapy support. Stop G-CSF ≥7 days before BM biopsy.	Do not administer G-CSF if active AML (stimulates leukemic proliferation). Exception: FLAG-IDA (intentional priming strategy).
DIC Management (APL)	Monitor fibrinogen, PT/PTT, D-dimer daily. Target fibrinogen >150 mg/dL, plt >50,000/mcL	Cryoprecipitate for fibrinogen replacement (10 units typically increases fibrinogen by ~50 mg/dL). FFP for PT correction.

SECTION 10: MONITORING DURING INTENSIVE THERAPY (AML-G)

Source: NCCN AML v3.2026 AML-G | Monitoring During Intensive Therapy

10.1 Induction Monitoring

Lab/Parameter	Frequency	Purpose/Action
CBC with differential	DAILY (differential daily during chemo; every other day after ANC >0.5 x 10⁹/L recovery)	Count recovery monitoring; detect neutrophil/platelet nadir; transfusion triggers.
Chemistry: electrolytes, LFTs, BUN/Cr, uric acid, phosphorus	At least DAILY during active treatment until TLS risk resolved	TLS monitoring; hepatotoxicity; renal function for dose adjustments.
Coagulation (PT/PTT/fibrinogen)	1–2x/week (daily if DIC present)	DIC surveillance, especially APL. Daily if DIC confirmed.
Bone Marrow Biopsy Day 14–21	Single assessment at D14–21 after induction start	Document hypoplasia (expected). If NOT hypoplastic → suspect persistent disease → repeat BM within 7 days.
BM Biopsy at Count Recovery	At time of hematologic recovery	Document remission. If initially abnormal cytogenetics → repeat cytogenetics. Consider MRD testing.
Nephrotoxic agent monitoring	More frequent during use (daily)	Dose adjustments for cytarabine, antimicrobials (vancomycin levels, etc.).
LVEF (ECHO/MUGA)	Before anthracycline-containing therapy and as clinically indicated	Cumulative cardiotoxicity monitoring. Repeat before each anthracycline/mitoxantrone course if high cumulative doses.
Neurological exam	Before EACH HiDAC dose (≥2 g/m²)	Cerebellar toxicity: nystagmus, ataxia, dysarthria, dysmetria. STOP cytarabine if present.
QTc (ECG)	Baseline + with QT-prolonging agents (quizartinib, ivosidenib, olutasidenib, ATO, sorafenib, revumenib)	QTcF >500 ms → hold/dose-reduce. Replete K+/Mg²+.
G6PD	Before rasburicase	CI if G6PD-deficient → use allopurinol.

10.2 Measurable Residual Disease (MRD) Assessment (AML-H)

• MRD assessment is now integral to AML management – guides post-remission strategy
• Methods: Multiparameter flow cytometry (MFC), qPCR (for NPM1, CBF-AML, PML::RARA), NGS-targeted deep sequencing
• NGS-based MRD for FLT3-ITD: sensitivity ≤10⁻⁵ preferred (per NCCN v3.2026 update)
• BM FLT3-ITD MRD ≥10⁻⁶ by highly sensitive NGS pre- or post-alloHCT → post-transplant gilteritinib maintenance recommended (new NCCN update v3.2026)
• MRD positivity in favorable-risk AML → consider alloHCT (changes management from consolidation to transplant)
• As there is no clear optimal management of MRD positivity → clinical trial preferred if available
• Venetoclax-based low-intensity therapy has demonstrated high rates of MRD reduction in MRD+ and oligoblastic AML

MRD testing method MATTERS: Flow cytometry (sensitivity ~10⁻³–10⁻⁴), qPCR (10⁻⁴–10⁻⁶), NGS (10⁻⁵–10⁻⁷). NPM1-mutant AML: qPCR in peripheral blood is highly sensitive and specific. CBF-AML: qPCR for KIT2A::RUNX1T1 or CBFB::MYH11. FLT3-ITD: NGS preferred over standard PCR.

SECTION 11: DOSE ADJUSTMENTS – ORGAN DYSFUNCTION

Drug	Renal Impairment	Hepatic Impairment	Other Adjustments
Cytarabine (≥2 g/m²)	CAUTION if CrCl <60 or rapidly rising Cr (TLS) → reduce to 1–1.5 g/m² or hold. Use 1–1.5 g/m² in age ≥60 y.	Minor hepatic metabolism; generally tolerated.	Age ≥60 y: reduce HiDAC dose to ≤1.5 g/m² to minimize neurotoxicity risk.
Daunorubicin	No specific dose reduction required (minimal renal excretion).	Bili 1.2–3 mg/dL: 75% dose. Bili >3 mg/dL: 50% dose.	Cumulative lifetime dose limit: ~550 mg/m² (reduced with prior RT).
Idarubicin	CrCl <10 mL/min: consider dose reduction.	Bili >2.5 mg/dL: do not administer. Bili 2–2.5 mg/dL: 50% dose.	Cumulative dose limit: ~150 mg/m².
Etoposide	CrCl 15–50 mL/min: 75% dose. CrCl <15 mL/min: consider 50%.	Bili 1.5–3: 50% dose. Bili >3: avoid.	Non-PVC tubing required.
MitoXANTRONE	Not renally eliminated; no adjustment generally needed.	Bili >3.4 mg/dL: consider dose reduction (not fully established).	Cumulative dose: monitor for cardiomyopathy. LVEF assessment required.
Venetoclax	No dose adjustment for renal impairment per label.	Severe hepatic impairment (Child-Pugh C): reduce to 100 mg QD.	CYP3A4 DDI adjustments mandatory (see Section 6).
Azacitidine	SCr rises during treatment: if SCr doubles → hold dose until SCr returns to normal.	Serum bicarb <20 mEq/L: reduce next cycle dose by 50%.
Decitabine	No formal recommendations; monitor closely.	No formal recommendations; monitor LFTs.
Midostaurin	No adjustment needed.	No adjustment for mild-moderate impairment.	CYP3A4 substrate: reduce with strong inhibitors; avoid inducers.
Gilteritinib	No dose adjustment needed (not renally excreted).	No dose adjustment for mild-moderate impairment.	CYP3A4 substrate. Avoid strong CYP3A4 inducers.
Quizartinib	No dose adjustment for renal impairment.	Moderate hepatic impairment: no adjustment required per label.	QTcF >500 ms → hold. Strong CYP3A4 inhibitors → reduce dose to 17.7 mg.
Ivosidenib	No dose adjustment needed.	No dose adjustment for mild-moderate.	QTc monitoring. Take consistently with or without food. Strong CYP3A4 inhibitors increase levels.
Enasidenib	No dose adjustment needed.	No dose adjustment.	Watch for differentiation syndrome. Bilirubin elevation can occur (IDH2 inhibition → unconjugated bilirubin ↑, not hepatotoxicity).
Olutasidenib	No formal adjustment.	Avoid in severe hepatic impairment.	QTc monitoring. CYP3A4 substrate.
GO (Gemtuzumab)	No dose adjustment.	Avoid in severe hepatic impairment or VOD/SOS.	VOD risk increases with prior or planned alloHCT. Do not administer if active hepatic VOD.
CPX-351	No dose adjustment.	Bilirubin 1.5–3 mg/dL: not adequately studied. Bili >3 mg/dL: avoid.	Monitor LVEF (daunorubicin component). Count recovery longer than standard 7+3.
Rasburicase	No dose adjustment.	No dose adjustment.	CONTRAINDICATED: G6PD deficiency, pregnancy, lactation. Single dose usually sufficient; repeat if needed.
Revumenib	No dose adjustment.	Severe impairment: not established.	Dose depends on CYP3A4 inhibitor co-administration. <40 kg: weight-based dosing per prescribing info.

ENASIDENIB: Elevated unconjugated bilirubin is a class effect of IDH2 inhibition (reduced UGT1A1 activity) – NOT true liver toxicity. Do NOT erroneously reduce/hold the drug based on isolated bilirubin elevation without other LFT abnormalities. Educate the team and document.

SECTION 12: KEY DRUG REFERENCE TABLE

Drug (Brand)	Class/MOA	Key Clinical Pearls / Counseling / Pharmacist Watchouts
Venetoclax (Venclexta)	BCL-2 inhibitor. Inhibits anti-apoptotic BCL-2 protein → restores apoptosis in leukemic cells.	Ramp-up dosing with HMA (100→200→400 mg) or LDAC (100→200→400→600 mg). DDI: Major CYP3A4 substrate: reduce dose with azole antifungals (posaconazole/voriconazole → strong; fluconazole → moderate). Avoid grapefruit, Seville oranges (CYP3A4 inhibition). Avoid strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin). TLS risk in C1: inpatient monitoring required. Check electrolytes Q6–8h during ramp-up. Take with food (increases absorption ~5-fold).
Midostaurin (Rydapt)	Multi-kinase inhibitor (FLT3-ITD/TKD, KIT, PDGFR). Inhibits FLT3 signaling → apoptosis.	Give on Days 8–21 of 7+3 (NOT with cytarabine/anthracycline, to avoid overlapping hematotoxicity). Continue as maintenance up to 12 cycles post-consolidation. N-desmethyl metabolite is active. DDI: CYP3A4 substrate: with azoles (alternative antifungal: micafungin – not a CYP3A4 inhibitor). Take with food (reduces GI toxicity). N/V is common (premed).
Quizartinib (Vanflyta)	Selective FLT3-ITD inhibitor (type II). ITD only, NOT TKD.	QuANTUM-First trial (OS benefit in FLT3-ITD+). Not active against TKD mutations (use gilteritinib or midostaurin instead). QTcF monitoring mandatory: baseline ECG, replete electrolyte prior QC. Dose is QTcF-guided: 26.5 mg C1D1–14; 53 mg if QTcF ≤450 ms. DDI: CYP3A4 substrate: strong inhibitors [ZA21] → reduce to 17.7 mg.
Gilteritinib (Xospata)	Selective FLT3 and AXL inhibitor (type I). Active against FLT3-ITD AND TKD mutations.	ADMIRAL trial: OS benefit in R/R FLT3+ AML vs. salvage chemo. Post-HCT maintenance for MRD+ FLT3-ITD (new NCCN update). Differentiation syndrome risk (fever, SOB/hypoxia, edema). Treat with dexamethasone 10 mg IV Q12h. QTc monitoring. CYP3A4 substrate (Avoid with strong CYP3A4 inducers).
ATRA – Tretinoin (Vesanoid)	Differentiating agent. Binds PML::RARA fusion protein → releases co-repressor complex → differentiates malignant promyelocytes.	START at first clinical suspicion of APL – do NOT wait for cytogenetics! Differentiation syndrome: ppx prednisone from D1. Switch to dexamethasone if differentiation syndrome develops. QTc monitoring (mild risk). Hepatotoxicity (monitor LFTs). Pseudotumor cerebri: headache, vision changes → reduce dose. Teratogenic: strict contraception required. Vitamin A toxicity (dry skin, cheilitis, elevated triglycerides).
Arsenic Trioxide (Trisenox)	Promotes PML::RARA degradation, induces apoptosis and differentiation of APL cells.	QTcF monitoring DAILY: QTcF >500 ms → HOLD. Replete K+, Mg²+, Ca²+ aggressively. Differentiation syndrome risk (same as ATRA). Peripheral neuropathy with prolonged use. Avoid concomitant QT-prolonging medications. Dilute in D5W or NS. Stable 24h at room temperature.
Gemtuzumab Ozogamicin (Mylotarg)	Anti-CD33 ADC (antibody-drug conjugate). Binds CD33 on leukemic cells → delivers calicheamicin → DNA damage.	Verify CD33 expression first! VOD/SOS risk: monitor LFTs, weight, RUQ pain. Risk increases with prior/subsequent alloHCT. Do not use in patients with hepatic VOD/SOS. Defibrotide available for VOD treatment. Infuse over 2 hours. Premedicate (acetaminophen + diphenhydramine). Thrombocytopenia – common and prolonged.
Ivosidenib (Tibsovo)	IDH1 inhibitor. Reduces 2-hydroxyglutarate (2-HG) production → restores normal differentiation.	AgIQ trial data (+ aza) for frontline use. IDH1 mutation required. Differentiation syndrome risk (similar to ATRA). Monitor and treat with dexamethasone. QTc prolongation: baseline ECG, electrolyte management. Food effect variable – take consistently. CYP3A4 substrate: dose adjust with strong inhibitors.
Enasidenib (Idhifa)	IDH2 inhibitor. Reduces 2-HG → restores myeloid differentiation.	IDH2 mutation required. Differentiation syndrome: more common in IDH2-R140 vs R172. Fever, dyspnea → dexamethasone. BILIRUBIN ELEVATION: Unconjugated hyperbilirubinemia is a class effect (NOT hepatotoxicity). Do NOT hold/stop for isolated elevated indirect bilirubin without other LFT derangement. Nausea/vomiting, diarrhea common.
Olutasidenib (Rezlidhia)	IDH1 inhibitor (oral, twice daily). Active against IDH1-R132 mutations.	IDH1-specific. Take with or without food. QTc monitoring. Differentiation syndrome risk. CYP3A4 substrate. Approved based on AUGMENT-101 trial.
Revumenib (Revuforj)	Menin inhibitor. Blocks menin-KMT2A interaction → disrupts oncogenic transcription in KMT2A-rearranged or NPM1-mutant AML.	DOSE IS CYP3A4 INHIBITOR DEPENDENT: 160 mg BID (with strong CYP3A4 inhibitor) vs. 270 mg BID (without). Verify concomitant antifungals! Differentiation syndrome risk. QTc prolongation monitoring. Weight-based dosing for <40 kg patients. NPM1 mutation OR KMT2A rearrangement required. FDA approved 2023.
Ziftomenib (Zilbrysq)	Menin inhibitor (oral, once daily). NPM1-mutant R/R AML.	NPM1 mutation required. FDA approved 2025 – newer agent, monitor for emerging safety data. Differentiation syndrome risk. DDI profile: CYP3A4 substrate – review concomitant medications.
Oral Azacitidine (Onureg / CC-486)	Oral hypomethylating agent. DNA methyltransferase inhibitor → re-expression of silenced tumor suppressor genes.	NOT bioequivalent to injectable azacitidine 75 mg/m²! Do NOT substitute. Approved for maintenance (300 mg PO Days 1–14 per 28-day cycle) in AML in CR/CRi post-intensive therapy. QUAZAR AML-001: OS benefit 24.7 vs. 14.8 months. Nausea: most common side effect. Take on empty stomach to minimize. No food restriction technically, but consistency matters.
Cytarabine (Cytosar-U)	Antimetabolite (pyrimidine analog). Incorporated into DNA → chain termination; inhibits DNA polymerase.	HiDAC (≥1 g/m²): steroid eye drops mandatory. Neuro exam before each HiDAC dose. CEREBELLAR TOXICITY: STOP immediately, no rechallenge. Flu-like syndrome: fever, myalgia (hours after standard-dose). Nausea/vomiting: antiemetics. Renal dose adjustment for CrCl <60 (if ≥2 g/m²). Age ≥60 y: max 1–1.5 g/m² for HiDAC.
CPX-351 (Vyxeos)	Liposomal formulation of cytarabine:daunorubicin (5:1 molar ratio). Liposomes preferentially taken up by leukemic cells.	Do NOT substitute with individual cytarabine + daunorubicin. Infuse over 90 minutes. Count recovery delayed vs. standard 7+3 – educate team. Cardiotoxicity monitoring (daunorubicin component). FDA approved for secondary AML, therapy-related AML, AML-MRC. Category 1 for age ≥60 y with secondary AML features (ADMIRAL trial framework).

SECTION 13: AML RESPONSE CRITERIA (AML-I)

Source: NCCN AML v3.2026 AML-I | Standard ELN 2022 Response Definitions

Response	Definition	Clinical Significance
CR (Complete Remission)	BM blasts <5%, no Auer rods, no extramedullary disease. ANC ≥1 x 10⁹/L. Platelets ≥100 x 10⁹/L. Transfusion independent.	Goal of induction therapy.
CRi (CR with incomplete count recovery)	CR criteria except ANC <1 x 10⁹/L and/or platelets <100 x 10⁹/L	Common after venetoclax-based regimens. Still meaningful response.
CRh (CR with partial hematologic recovery)	CR criteria except ANC ≥0.5 but <1 x 10⁹/L and/or platelets ≥50 but <100 x 10⁹/L	Partial count recovery.
MLFS (Morphologic Leukemia-Free State)	BM blasts <5%, no complete count recovery	Meaningful response in venetoclax context; proceed with therapy.
MRD-negative CR (CR MRD-)	CR + no detectable MRD by flow, PCR, or NGS	Best prognostic outcome; may allow de-escalation of post-remission therapy in favorable risk.
Primary Refractory	Inability to attain CR, CRh, or CRi following ≥2 courses of intensive induction therapy	Poor prognosis; consider salvage and alloHCT evaluation.
Relapse	Reappearance of leukemic blasts in peripheral blood OR ≥5% blasts in BM (not attributable to recovery)	Distinguish from BM regeneration post-consolidation.
MRD Relapse (NEW v3.2026)	Conversion from MRD negativity to MRD positivity (any method)	New category added per latest update. Treatment implications evolving.

In venetoclax-based regimens, CRi (without complete platelet/ANC recovery) is a valid and expected response. Prolonged cytopenias do NOT always indicate treatment failure. BM biopsy at days 21–28 is the guide – if <5% blasts, proceed with dose modification per AML-J algorithm.

SECTION 14: MASTER CLINICAL PEARLS & PHARMACIST WATCHOUTS

🔑 Top 20 Clinical Pearls for AML Pharmacotherapy

💎 1. ATRA in APL: Start IMMEDIATELY at first clinical suspicion (life-saving, avoid fatal DIC). DONT wait for cytogenetics.
💎 2. G6PD check prior rasburicase (risk for severe hemolytic anemia). If urgent/G6PD status unknown, consider allopurinol.
💎 3. CPX-351 ≠ 7+3: The liposomal formulation has different PK/toxicity. Do NOT substitute components. Count recovery takes longer. Category 1 for secondary/therapy-related AML in age ≥60 y.
💎 4. Venetoclax DDI is CRITICAL: Posaconazole (strong CYP3A4 inhibitor) increases venetoclax exposure significantly. Dose must be reduced (per package insert). Document adjustment in chart.
💎 5. Quizartinib: QTcF >500 ms → HOLD. ITD-specific (does NOT cover TKD). Different from midostaurin/gilteritinib which cover both ITD and TKD.
💎 6. HiDAC Eye Drops: Prednisolone 1% BID to each eye from Day 1 through 24–72h post-cytarabine. If not ordered → chemical keratoconjunctivitis. This is a MUST-order item.
💎 7. HiDAC Neurotoxicity: Age ≥60 y and CrCl <60 mL/min → highest risk. Neuro exam before EACH dose. Ataxia/nystagmus/dysarthria = STOP permanently, no rechallenge with ≥2 g/m².
💎 8. Enasidenib Bilirubin: Elevated unconjugated bilirubin is expected (class effect of IDH2 inhibition, not hepatotoxicity). Educate team. Do NOT hold drug for isolated bilirubin rise without other LFT abnormalities.
💎 9. Revumenib dose depends on antifungal: 160 mg BID WITH strong CYP3A4 inhibitor (posaconazole/voriconazole). 270 mg BID WITHOUT. This is a critical prescribing and verification point.
💎 10. Oral azacitidine (Onureg) 300 mg ≠ injectable azacitidine 75 mg/m². Different bioavailability, different indication (maintenance). Do NOT interchange.
💎 11. TLS in venetoclax/AML: Inpatient monitoring during cycle 1 ramp-up is strongly recommended. WBC must be <25 x 10⁹/L before starting. Electrolytes Q6–8h during ramp-up.
💎 12. FLT3-ITD MRD ≥10⁻⁶ by NGS pre/post-alloHCT: Post-transplant gilteritinib maintenance is now recommended per NCCN v3.2026. This is a new indication.
💎 13. Etoposide: Use non-PVC tubing (DEHP leaching from PVC). Monitor for hypersensitivity. Secondary AML/MDS risk with cumulative use.
💎 14. G-CSF: STOP ≥7d before bone marrow biopsy to avoid misinterpreting neutrophil recovery as persistent leukemia.
💎 15. APL Differentiation Syndrome: Dexamethasone 10 mg IV Q12h at first sign. Generally do NOT stop ATRA/ATO for mild-moderate syndrome. Do NOT confuse with infection.
💎 16. IDH inhibitor differentiation syndrome (ivosidenib, enasidenib, olutasidenib, revumenib): same principle – dexamethasone, generally continue drug unless severe.
💎 17. Midostaurin + azole antifungals: Significant CYP3A4 DDI. Institutional practice often switches to micafungin (not a CYP3A4 inhibitor) during midostaurin therapy.
💎 18. TP53-mutant AML: Lowest venetoclax benefit. NCCN preferred recommendation = CLINICAL TRIAL. Do not assume venetoclax will be effective.
💎 19. ATO QTcF monitoring: Obtain ECG and electrolytes (K+, Mg²+, Ca²+) DAILY during ATO therapy. QTcF >500 ms → HOLD until corrected.
💎 20. Response criteria update: MRD relapse is now a distinct category per NCCN v3.2026 (conversion from MRD-neg to MRD-pos). FLT3-ITD MRD guidance now explicitly guides post-HCT maintenance decision.

⚠️ Top 10 Pharmacist Watchouts During Multidisciplinary Rounds

⚠️ 1. VERIFY FLT3 mutation type before FLT3 inhibitor selection: Quizartinib = ITD ONLY. Midostaurin/Gilteritinib = ITD AND TKD. Wrong drug selection is a clinically significant error.
⚠️ 2. VENETOCLAX DOSE ADJUSTMENT WITH ANTIFUNGALS: At every cycle review, check concurrent antifungals and confirm venetoclax dose has been adjusted. This is the #1 pharmacist DDI catch in AML.
⚠️ 3. CONFIRM CD33 EXPRESSION before gemtuzumab ozogamicin – both for induction and single-agent use. Check the flow cytometry or IHC report.
⚠️ 4. MONITOR CUMULATIVE ANTHRACYCLINE DOSE: Track daunorubicin (from 7+3 and CPX-351), idarubicin, mitoXANTRONE (anthracycline equivalent). Use conversion factors. Lifetime limit considerations before each course.
⚠️ 5. CEREAL NEUROTOX NEURO EXAM DOCUMENTATION: Verify that the bedside neuro exam was done before every HiDAC dose and is DOCUMENTED. Flag if not done.
⚠️ 6. CHECK QTcF AT EVERY CYCLE: For quizartinib, ivosidenib, olutasidenib, ATO, sorafenib, revumenib. Review ECG, current K+/Mg²+ levels, and concomitant QT-prolonging medications.
⚠️ 7. ANTIMICROBIAL PROPHYLAXIS DDI REVIEW: Posaconazole (preferred antifungal in AML per NCCN) is a strong CYP3A4 inhibitor. Always review it against all concurrent targeted therapies.
⚠️ 8. RASBURICASE + ALLOPURINOL = CONTRAINDICATED COMBINATION. Cannot use both simultaneously. Rasburicase converts uric acid to allantoin; allopurinol blocks xanthine oxidase. If rasburicase given, stop allopurinol.
⚠️ 9. STEROID EYE DROPS ORDER VERIFICATION: For every HiDAC course, verify prednisolone 1% eye drops are ordered bilaterally, starting Day 1, continuing 24–72h post-cytarabine. Common omission error.
⚠️ 10. ENASIDENIB BILIRUBIN ALERT: If team plans to hold/reduce enasidenib for isolated bilirubin elevation → intervene. Unconjugated hyperbilirubinemia is a class effect of IDH2 inhibition. Distinguish from true hepatotoxicity (transaminase elevation pattern).

SECTION 15: QUICK REFERENCE CARDS

15.1 Transfusion Thresholds

Blood Product	Threshold (NCCN AML-F)	Special Circumstances
RBCs	Hgb ≤7–8 g/dL (or symptomatic anemia)	Leukocyte-depleted; CMV-neg for HCT candidates; irradiated for alloimmunized or pre-HCT.
Platelets	Plt <10,000/mcL OR any active bleeding	Alloimmunized: HLA-matched/crossmatch-compatible products. In APL: maintain >50,000/mcL due to DIC risk.
FFP/Cryoprecipitate	APL/DIC: Fibrinogen <150 mg/dL → cryoprecipitate; PT prolonged → FFP	DIC in APL is a hematologic emergency. Replace aggressively.

15.2 TLS Monitoring Protocol Summary

Timepoint	Action
Before venetoclax initiation	WBC <25 x 10⁹/L (hydroxyurea/leukapheresis). Allopurinol or rasburicase. G6PD check. IV hydration.
During ramp-up (Cycle 1 D1–4)	Inpatient. Labs (electrolytes, uric acid, Cr, phos, LDH) Q6–8h after initiation x24h after maximum dose.
After maximum dose achieved	Daily chemistry monitoring until TLS risk resolved.
Electrolyte management	K+, Phos, Ca²+, uric acid. Sodium polystyrene for hyperkalemia (use cautiously); sevelamer/calcium carbonate for hyperphosphatemia; calcium for hypocalcemia; rasburicase/allopurinol for hyperuricemia.

15.3 Differentiation Syndrome – Rapid Response Card

Feature	Detail
Trigger	ATRA, ATO, IDH inhibitors (ivosidenib, enasidenib, olutasidenib), FLT3 inhibitors (gilteritinib), Menin inhibitors (revumenib, ziftomenib)
Signs/Symptoms	Fever ≥38°C, dyspnea, pulmonary infiltrates, pleural/pericardial effusion, hypoxia, weight gain ≥5 kg, hypotension, renal failure, edema
Treatment	Dexamethasone 10 mg IV Q12h until resolution (typically ≥3 days)
Drug management	Do NOT stop the causative agent unless Grade 3–4 refractory to dexamethasone
Differentiate from infection	Blood cultures, CXR, clinical judgment – both can coexist
Special APL note	Prednisone prophylaxis from ATRA Day 1 (switch to dexamethasone if DS develops)

15.4 QTc Management Quick Card

Drug	QTcF Threshold	Action if Exceeded
Quizartinib	>500 ms (or >450 ms to escalate from 26.5 to 53 mg)	Hold. Replete K+/Mg²+. Recheck ECG. If resolves to ≤480 ms, restart at lower dose. Maintain 26.5 mg if QTcF >500 ms at any time.
ATO (Arsenic Trioxide)	>500 ms	HOLD. Aggressively replete electrolytes. Recheck in 24h. Restart only when <450 ms.
Ivosidenib	>500 ms	Hold. Replete electrolytes. Restart at reduced dose if indicated.
Olutasidenib	>500 ms	Hold/dose-reduce per prescribing information.
Revumenib	≥500 ms or increase >60 ms from baseline	Hold. Electrolyte repletion. Restart at reduced dose per prescribing info.
Sorafenib	>500 ms	Hold. Manage electrolytes. Reassess benefit/risk.

REFERENCE: NCCN Clinical Practice Guidelines in Oncology – Acute Myeloid Leukemia, Version 3.2026, November 24, 2025. NCCN Chemotherapy Order Template AML34 (MEC), v1.2026. ELN 2022 Risk Stratification (Döhner H, et al. Blood 2022;140:1345-1377). Compiled for educational use by a Hematology/Oncology Pharmacotherapy Specialist.

Checklist